Schrödinger has discontinued development of its CDC7 inhibitor drug candidate, SGR-2921, following the deaths of two patients with acute myeloid leukemia (AML) during a phase I dose-escalation clinical trial. Despite initial evidence of monotherapy activity and promising preclinical profiles, the association with treatment-related fatalities and adverse safety signals has prompted the company to cease further investigation of this compound. Schrödinger continues to pursue other oncology programs but regards the termination as a prudent decision prioritizing patient safety.